methyl (8E,10Z,12E,14E)-17-phenyl-7,16,17-tris(phosphanyloxy)heptadeca-8,10,12,14-tetraenoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl (8E,10Z,12E,14E)-17-phenyl-7,16,17-tris(phosphanyloxy)heptadeca-8,10,12,14-tetraenoate
• 化学式: C₂₄H₃₅O₅P₃
• 分子量: 496.5
• InChiKey: ISOSEFMIRASRRA-VDLDGDPESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  32
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• USE OF DOCASATRIENES, RESOLVINS, AND THEIR STABLE ANALOGS IN THE TREATMENT OF AIRWAY DISEASES AND ASTHMA
  申请人：The Brigham and Women's Hospital, Inc.

  公开号：US20140179630A1

  公开（公告）日：2014-06-26

  The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.